What is the equivalent dose of Divigel (estradiol) when converting a patient from Estrogel (estradiol)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Estrogel to Divigel Conversion

When converting from Estrogel to Divigel, use a 2:1 ratio based on estradiol content: Estrogel 1.5 mg (2.5 g gel) converts to Divigel 0.75 mg, and Estrogel 0.75 mg (1.25 g gel) converts to Divigel 0.375 mg. 1, 2

Understanding the Formulation Differences

The two products differ fundamentally in their estradiol concentration and cannot be compared solely on dose alone:

  • Estrogel contains 0.06% estradiol (w/w), applied over 720 cm² surface area 3, 4
  • Divigel contains 0.1% estradiol (w/w), applied over 200-400 cm² surface area 5, 6, 3

Despite these differences, in vitro studies demonstrate bioequivalence at recommended dose levels, with similar percutaneous penetration rates of approximately 17-18% of applied dose over 24 hours 3.

Specific Conversion Recommendations

Standard Dose Conversion

  • Estrogel 1.5 mg (2.5 g gel) → Divigel 0.75 mg 2, 4
  • Estrogel 0.75 mg (1.25 g gel) → Divigel 0.375 mg 2, 4

Clinical Efficacy Evidence

Network meta-analysis demonstrates that Divigel 0.5 mg shows similar efficacy to Estrogel 0.75 mg and 1.5 mg for both hot flush frequency and severity 2. However, Estrogel 1.5 mg was paradoxically associated with the smallest reduction in hot flush frequency, suggesting non-linear dose-response 2.

Application Technique Matters

Critical caveat: Divigel's higher bioavailability from smaller application areas (200 cm²) means application technique significantly impacts absorption 6. When converting:

  • Apply Divigel to 200-400 cm² area (thigh, abdomen, or upper arm) 1, 6
  • Avoid washing the application site for at least 30 minutes, as washing reduces bioavailability by approximately 50% and significantly reduces peak plasma concentrations 6
  • Smaller application areas (200 cm²) provide 2-fold higher bioavailability than larger areas 6

Monitoring After Conversion

Reassess symptom control at 2-3 months after conversion, as both formulations show statistically significant reductions in vasomotor symptoms by week 2 that are maintained throughout treatment 5, 4. If symptoms persist:

  • Increase Divigel dose from 0.5 mg to 1.0 mg, which provides the best efficacy profile for hot flush frequency (mean difference of 3.91 hot flushes/week vs placebo) 2
  • Note that Divigel 1.0 mg carries higher risk of treatment-related adverse events compared to lower doses 2

Endometrial Protection Requirement

Women with an intact uterus must receive progestin supplementation regardless of which estradiol gel formulation is used 1, 7:

  • 200 mg vaginal or oral micronized progesterone daily for 12-14 days every 28 days (sequential regimen) 1, 7
  • Alternative: 10 mg medroxyprogesterone acetate for 12-14 days monthly 1
  • Expect withdrawal bleeding after each progestin cycle with sequential dosing 7

Safety Considerations

Both transdermal gels maintain the cardiovascular safety advantage over oral estradiol, with neutral effect on venous thromboembolism risk (OR 0.9) compared to oral estradiol (OR 4.2) 1. Treatment-emergent adverse events leading to discontinuation were not statistically significantly different from placebo for either formulation 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.